These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 26314797

  • 1. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J, Chen DT, Fulp WJ, Yoder SJ, Zhang Y, Georgeades C, Husain K, Centeno BA, Magliocco AM, Coppola D, Malafa M.
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [Abstract] [Full Text] [Related]

  • 2. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
    Permuth-Wey J, Chen YA, Fisher K, McCarthy S, Qu X, Lloyd MC, Kasprzak A, Fournier M, Williams VL, Ghia KM, Yoder SJ, Hall L, Georgeades C, Olaoye F, Husain K, Springett GM, Chen DT, Yeatman T, Centeno BA, Klapman J, Coppola D, Malafa M.
    PLoS One; 2015 Sep; 10(1):e0116869. PubMed ID: 25607660
    [Abstract] [Full Text] [Related]

  • 3. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D, Damaskos C, Spartalis E, Papalampros A, Vernadakis S, Dimitroulis D, Griniatsos J, Felekouras E, Nikiteas N.
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [Abstract] [Full Text] [Related]

  • 4. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K, Ohtsuka T, Date K, Fujimoto T, Matsunaga T, Kimura H, Watanabe Y, Miyazaki T, Ohuchida K, Takahata S, Ishigami K, Oda Y, Mizumoto K, Nakamura M, Tanaka M.
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [Abstract] [Full Text] [Related]

  • 5. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M, Makino N, Ikeda Y, Matsuda A, Ito M, Kakizaki Y, Saito Y, Ishizawa T, Kobayashi T, Furukawa T, Ueno Y.
    PLoS One; 2016 Jul; 11(7):e0158669. PubMed ID: 27380024
    [Abstract] [Full Text] [Related]

  • 6. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N, Ohtsuka T, Kono H, Fujiwara K, Oda Y, Aishima S, Ito T, Ishigami K, Tokunaga S, Ohuchida K, Takahata S, Nakamura M, Mizumoto K, Tanaka M.
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [Abstract] [Full Text] [Related]

  • 7. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
    Chang X, Yu C, Li J, Yu S, Chen J.
    Int J Med Sci; 2017 Jul; 14(5):412-418. PubMed ID: 28539816
    [Abstract] [Full Text] [Related]

  • 8. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms.
    Zhuge X, Zhou H, Chen L, Chen H, Chen X, Guo C.
    BMC Cancer; 2021 Nov 20; 21(1):1253. PubMed ID: 34800987
    [Abstract] [Full Text] [Related]

  • 9. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T.
    J Pathol; 2013 Nov 20; 231(3):335-41. PubMed ID: 23893889
    [Abstract] [Full Text] [Related]

  • 10. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E, Duran-Sanchon S, Vila-Casadesús M, Moreira L, Ginès À, Cuatrecasas M, Lozano JJ, Bujanda L, Castells A, Gironella M.
    Clin Transl Gastroenterol; 2019 Apr 20; 10(4):e00029. PubMed ID: 31009404
    [Abstract] [Full Text] [Related]

  • 11. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR, Jang JY, Kang MJ, Park T, Lee SY, Jung W, Chang J, Shin Y, Han Y, Kim SW.
    J Hepatobiliary Pancreat Sci; 2015 Sep 20; 22(9):699-707. PubMed ID: 26178866
    [Abstract] [Full Text] [Related]

  • 12. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S, Onaya H, Hiraoka N, Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T.
    Pancreas; 2009 Jan 20; 38(1):8-16. PubMed ID: 18665010
    [Abstract] [Full Text] [Related]

  • 13. Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas.
    You L, Ma L, Zhao WJ, Zhao YP, Dai MH.
    Clin Chim Acta; 2016 Feb 15; 454():89-93. PubMed ID: 26746574
    [Abstract] [Full Text] [Related]

  • 14. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts.
    Vila-Navarro E, Vila-Casadesús M, Moreira L, Duran-Sanchon S, Sinha R, Ginés À, Fernández-Esparrach G, Miquel R, Cuatrecasas M, Castells A, Lozano JJ, Gironella M.
    Ann Surg; 2017 Jun 15; 265(6):1226-1234. PubMed ID: 27232245
    [Abstract] [Full Text] [Related]

  • 15. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas.
    Akimoto Y, Nouso K, Kato H, Miyahara K, Dohi C, Morimoto Y, Kinugasa H, Tomoda T, Yamamoto N, Tsutsumi K, Kuwaki K, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Okada H, Amano M, Nishimura S, Yamamoto K.
    Pancreatology; 2015 Jun 15; 15(4):432-8. PubMed ID: 26052067
    [Abstract] [Full Text] [Related]

  • 16. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B, Izetti P, Gregório C, Macedo GS, Castro MA, Osvaldt AB, Matte U, Ashton-Prolla P.
    Pancreas; 2016 Jan 15; 45(1):84-92. PubMed ID: 26262588
    [Abstract] [Full Text] [Related]

  • 17. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kobayashi S, Kojima M, Miyauchi H, Asano T.
    J Hepatobiliary Pancreat Sci; 2010 Nov 15; 17(6):798-802. PubMed ID: 19727540
    [Abstract] [Full Text] [Related]

  • 18. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N, Sato N, Mori Y, Tamura T, Higure A, Yamaguchi K.
    Eur J Surg Oncol; 2013 Jun 15; 39(6):554-8. PubMed ID: 23506840
    [Abstract] [Full Text] [Related]

  • 19. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
    Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K, Satoh K.
    Int J Oncol; 2015 Feb 15; 46(2):539-47. PubMed ID: 25384963
    [Abstract] [Full Text] [Related]

  • 20. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Kobayashi N, Sugimori K, Shimamura T, Hosono K, Watanabe S, Kato S, Ueda M, Endo I, Inayama Y, Maeda S, Nakajima A, Kubota K.
    Pancreatology; 2012 Feb 15; 12(2):141-5. PubMed ID: 22487524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.